Mutations in the ataxia telangiectasia mutated (ATM) gene cause chromosomal instability leading to ataxia telangiectasia (AT). The AT phenotype classically combines cerebellar ataxia, vermal atrophy, athetosis, ocular motor abnormalities, physical and mental retardation, hypogonadism, and telangiectasia predominantly of the face and eyes. Affected persons commonly suffer from hypogammaglobulinemia and functional T-cell defects and have an increased risk of developing acute leukemias and lymphomas. As a consequence, life expectancy is decreased due to recurrent infections and malignancies. 1, 2 We report on a 13-year-old boy with AT who developed EBV-associated lymphoproliferation and was cured by chemotherapy followed by allogeneic stem cell transplantation (HSCT) from his HLA-identical sibling. Until he developed lymphoproliferation, the patient was seen as an outpatient for his known AT caused by compound heterozygosity for two splice site mutations within the ATM gene (IVS38-2A4G in exon 39 and c.6095G4A (R2032K) in exon 43). The patient's parents were each heterozygous for one of the mutations and the patient's clinically unaffected brother, who was the bone marrow donor, was heterozygous for IVS38-2A4G. ATM kinase activity was not analyzed before bone marrow transplantation (BMT). However, the main effect of the c.6095G4A (R2032K) mutation is aberrant splicing causing a frameshift mutation and premature termination of transcription. The resulting protein will lack its kinase domain and ATM expression will be low or absent. The ATM kinase activity on the other allele (IVS38A4G) was expected to be low to normal. At this stage, the patient showed mental and growth retardation, and suffered from cellular and humoral immunodeficiency ( Table 1) , his endocrine system showed prepubertal values with a clinical Tanner stage 1. To our knowledge, this is the first report on a child with AT and non-Hodgkin lymphoma (NHL) surviving after HSCT.
In the age of 13 years, he presented with cervical lymphadenopathy, a prominent Waldeyer's lymphatic ring, and enlarged tracheal and intrapulmonary lymph nodes. In addition, there was a cutaneous infiltration of the abdominal wall, infiltration of the right mastoid bones and the right middle ear. Histopathologic and immunophenotypic work-up showed a CD20-and CD30-positive EBV-positive polymorphic lymphoproliferation (Figures 1a-c) , which was treated with valganciclovir and anti-CD20-antibodies (Rituximab, Roche, Basel, Switzerland, 6 × 375 mg/m 2 ). Until that time, no Igs had been given to the patient for his immunodeficiency. Within 6 weeks, EBV-reverse transcription-PCR became negative and valganciclovir was stopped after skin toxicity had occurred. CR of the disease in the primarily involved lymph nodes was achieved after 6 courses of anti-CD20-antibodies with the exception of a small residual upper cervical node. Following anti-CD20 therapy, he was given IV-Igs on a 3-week schedule.
Two months later the patient presented with a one-sided enlargement of his left tonsil. Tonsillectomy was performed and, at this time, work-up revealed an EBV-positive B-cell NHL (Figures 1d and e) . Based on the initial imaging studies, he was stratified into risk group 2 of the NHL-BFM Berlin-FrankfurtMünster (BFM) 2012 registry (St Judes stage 2 with involvement of cervical lymph nodes and Waldeyer's lymphatic ring) and treated with upfront dexamethasone followed by reduced A 
Chemotherapy was tolerated well (grade ⩾ 3 toxicity: hematology and liver) and CR was achieved. Hematuria was observed only once on day 10 of the first B 4 block. It resolved spontaneously without IV hydration or bladder irrigation.
Because the underlying immunodeficiency and recurrent EBV-associated lymphoproliferation, the decision was made to proceed with HSCT from his clinically normal HLA-identical adult sibling who was heterozygous for the IVS38-2A4G mutation in exon 39 of the ATM gene. At this stage, there was no evidence of hepatic or renal failure (slightly elevated gamma-GT (246 U/L, normal o55U/L) and otherwise normal liver enzymes, normal creatinine clearance of 128 mL/min and normal hepatic Figure 1 . B-lymphoproliferative disease: Effacement of lymph node architecture with prevailing small-to medium-sized lymphocytes with only scattered blasts (Giemsa stain, (a)). Scattered blasts were positive for CD30 (immunohistochemistry anti-CD30, peroxidase visualization, (b)) and EBV-associated RNA (EBER, in situ hybridization, (c)). B-lymphoma: Resection specimen of the tonsil at the time of progression showed sheets of medium-to large-sized blasts with an accompanying mixed infiltrate, rich in polymorphic granulocytes (d). The blasts were positive for CD30 (e) and EBER (f) ((d): Giemsa stain; (e): immunohistochemistry anti-CD30, peroxidase visualization; (f): in situ hybridization).
texture on ultrasound. Alpha-fetoprotein (AFP) was elevated to 293 ng/mL. As AT patients have shown to be especially prone to alkylating agent-induced toxicity, a conditioning regimen based on the Fanconi anemia protocol GEFA-02 4 was used. The total dose of fludarabine was 180 mg/m 2 , IV busulfan (Busilvex, Pierre Fabre, Freiburg, Germany) 1.6 mg/kg and cyclophosphamide 40 mg/kg. Given a CD20-positive malignancy and the availability of an HLA-identical sibling donor, two more doses of Rituximab (2 × 375 mg/m 2 ) were given and no T-cell-depleting antibodies were used for conditioning. Bone marrow was used containing 2.95 × 10 8 nucleated cells. Neutrophil engraftment occurred on day +19 and donor chimerism has always been 100% starting day +32 through his last follow-up at 1 year. During the early transplant course, the boy developed severe mucosal toxicity including gastrointestinal bleeding. Massive BKV-associated hemorrhagic cystitis not responding to conventional treatment strategies required bladder irrigation and finally bilateral longterm ureterocutaneostomy. As an additional treatment-related complication, severe veno-occlusive disease (VOD) developed including hepatomegaly, reversion of portal venous blood flow and ascites requiring drainage and pleural effusions. VOD was treated with defibrotide and protein C. During one of the several septic episodes, he developed an adult-type respiratory distress syndrome making mechanical ventilation necessary. No acute or chronic GvHD was observed.
After HSCT, CD19+ and CD16+/CD56+ cells reconstituted 10 months post HSCT, whereas total lymphocyte count and CD8+ cells normalized at 18 months and CD3+ and CD4+ cells at 30 months post HSCT (Table 1) . Ig reconstitution began at 6 months with normalizing IgM values, followed by reconstitution of IgG levels at 10 months and finally reconstitution of IgA levels at 30 months. IgG2 levels, however, remained slightly reduced even after 30 months post BMT (Table 1) . Interestingly, AFP levels at 30 months post HSCT are even higher than at diagnosis of EBV-positive lymphoproliferation (443 vs 293 ng/mL). Endocrine function has developed with normal thyroid and adult sex hormone values and a clinical Tanner stage of 4. However, IGF-1 is low, probably indicating the beginning of growth hormone deficiency.
Urinary continence was reestablished by closing the ureterocutaneostomies and augmenting the urinary bladder with an ileum conduit 18 months after ureterocutaneostomy.
Unexpectedly, neurologic function slowly recovered after HSCT as well. During modified NHL-BFM treatment, ataxia had deteriorated and VCR-associated neuropathy occurred, finally not allowing him to walk, stand or sit without support. Selfsupported eating became cumbersome due to deteriorating ataxia. Two years after HSCT, he is now able to sit and stand without support. He even walks a few steps with assistance. His mental stage remains unchanged; he attends a special schooling program for intellectually disabled children.
So far only a single long-term surviving patient with AT receiving HSCT has been reported in the literature. 5 A second patient, conditioned with a fully ablative regimen containing treosulfan and fludarabine, engrafted and showed immune reconstitution. He died from hepatic failure 32 months after HSCT while on treatment for a post-transplant lymphoproliferative disorder. 6 Finally, another patient reported by Ussowicz et al.
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never went into remission from his acute leukemia and died from progressive disease after transplant. The ethical justification for performing HSCT on a patient with AT is highly controversial. The patient reported here suffered from a congenital condition accompanied with recurrent lifethreatening infections due to immunodeficiency, increased risk of malignant diseases, limited life expectancy and impaired mental abilities. For these patients, no curative treatment is known. However, there is evidence from an Atm-deficient mouse model that the immune system of AT patients can be restored and lymphoma can be prevented by BMT. 7 As in other chromosomal instability syndromes and in a young child with AT and ALL, HSCT has contributed to a positive treatment outcome, 5, [8] [9] [10] the mouse model data suggest that even for AT patients with EBV-driven NHL, HSCT might be of benefit. Furthermore, only two AT patients with mature B-cell non-Hodgkin lymphoma (B-NHL) (not EBV driven) were described earlier. Both patients were treated with chemotherapy, one reached continuous CR and the other died of infectious complications due to the underlying disease.
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The remarkable toxicity of a regimen that is usually welltolerated even by Fanconi anemia patients was unexpected, although abnormal liver function is often seen in AT patients and VOD can even occur spontaneously. Postmortem liver histopathology of otherwise asymptomatic AT patients showed a broad spectrum of preexisting hepatic morbidities ranging from hepatitis with periportal fibrosis to cirrhosis. 12 This suggests hepatic involvement on the basis of AT and a propensity to develop hepatic toxicity.
Ussowicz et al. 5 reported an AT patient who was transplanted with strikingly low acute toxicity. This patient was 3 years old and had developed ALL. He was treated with ALL-BFM protocol HR courses with reduced doses of cytarabine, ifosfamide and methotrexate. He tolerated this therapy well and achieved remission, similar to our patient. In contrast to our patient, who developed life-threatening toxicity in several organ systems, his conditioning was reasonably well-tolerated. The employed dose of busulfan was higher than in our patient (2 mg/kg). Of note, no cyclophosphamide was used in combination. OKT3 and ATG were given for T-cell depletion before receiving PBSCs from an HLA-identical brother. One might speculate that the higher age of our patient allowed for a longer time to accumulate chromosomal breaks and organ damage. Alternatively, reduced toxicity in the young boy could have been a result of omitting cyclophosphamide known to aggravate sulfhydryl (SH)-group depletion in combination with busulfan.
Alkylating agents show substantial toxicity in AT patients. They seem to trigger increased pulmonary toxicity after BCNU 13 and severe urinary bladder toxicity by even low doses of cyclophosphamide. 14 Sandoval et al. 13 reported that hemorrhagic cystitis was common in AT patients with lymphoid malignancies treated with 41200 mg/m 2 (40 mg/kg) of cyclophosphamide. Nevertheless, he recommended not to reduce cyclophosphamide for the treatment of lymphoid malignancies, but to increase commonly used prophylactic doses of 2-mercaptoethanesulfonic acid sodium salt. On the other hand, severe hemorrhagic cystitis has been reported in AT patients without chemotherapy as a Abbreviations: ARA-C = cytarabine; CPM = cyclophosphamide; DOX = doxorubicine; DXM = dexamethasone; ETO = etoposide; MTX = methotrexate.
Letter to the Editor result of bladder wall telangiectasis and JC virus infection. Thus, underlying vessel abnormalities probably contributed to toxicity. 15, 16 Based on this single case experience, one might speculate that AT patients will benefit from conditioning regimens without irradiation or alkylating agents. Especially cyclophospahmide may not be advisable because of its propensity to cause hemorrhagic cystitis in patients predisposed by vascular abnormalities. With AT being a cancer predisposition syndrome, it remains unclear whether HSCT containing alkylating agents will result in the earlier development of consecutive malignancies as has been suggested for Fanconi anemia. 17 
